Brand Name | Status | Last Update |
---|---|---|
rystiggo | Biologic Licensing Application | 2024-06-25 |
Expiration | Code | ||
---|---|---|---|
rozanolixizumab, Rystiggo, UCB, Inc. | |||
2030-06-26 | Orphan excl. |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | — | 2 | 6 | — | — | 7 |
Muscle weakness | D018908 | HP_0001324 | — | — | 2 | 6 | — | — | 7 |
Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | 1 | 3 | — | — | 4 |
Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 1 | 3 | — | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic inflammatory demyelinating polyradiculoneuropathy | D020277 | EFO_1000868 | G61.81 | — | 2 | — | — | 1 | 3 |
Polyradiculoneuropathy | D011129 | EFO_1001116 | — | — | 2 | — | — | — | 2 |
Glioma | D005910 | EFO_0000520 | — | — | 1 | — | — | — | 1 |
Autoimmune diseases of the nervous system | D020274 | — | — | — | 1 | — | — | — | 1 |
Hashimoto disease | D050031 | EFO_0003779 | E06.3 | — | 1 | — | — | — | 1 |
Encephalitis | D004660 | HP_0002383 | — | — | 1 | — | — | — | 1 |
Partial epilepsies | D004828 | EFO_0004263 | — | — | 1 | — | — | — | 1 |
Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | 1 | — | — | — | 1 |
Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Polyneuropathies | D011115 | EFO_0009562 | A69.22 | — | — | — | — | 1 | 1 |
Drug common name | Rozanolixizumab |
INN | rozanolixizumab |
Description | Rozanolixizumab, sold under the brand name Rystiggo, is a monoclonal antibody used for the treatment of myasthenia gravis. Rozanolixizumab is a humanized and chimeric monoclonal antibody; and is a neonatal Fc receptor blocker.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | >6FGB:H|1519.g57- Heavy chain
EVPLVESGGGLVQPGGSLRLSCAVSGFTFSNYGMVWVRQAPGKGLEWVAYIDSDGDNTYYRDSVKGRFTISRDNAKSSLY
LQMNSLRAEDTAVYYCTTGIVRPFLYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCAA
>6FGB:L|1519.g57- Light chain
DIQMTQSPSSLSASVGDRVTITCKSSQSLVGASGKTYLYWLFQKPGKAPKRLIYLVSTLDSGIPSRFSGSGSGTEFTLTI
SSLQPEDFATYYCLQGTHFPHTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ
SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
PDB | 6FGB |
CAS-ID | 1584645-37-3 |
RxCUI | — |
ChEMBL ID | CHEMBL4297820 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB14919 |
UNII ID | P7186074QC (ChemIDplus, GSRS) |